JPS60109522A - 神経病の治療のためのビロバリド含有製剤組成物 - Google Patents
神経病の治療のためのビロバリド含有製剤組成物Info
- Publication number
- JPS60109522A JPS60109522A JP59225657A JP22565784A JPS60109522A JP S60109522 A JPS60109522 A JP S60109522A JP 59225657 A JP59225657 A JP 59225657A JP 22565784 A JP22565784 A JP 22565784A JP S60109522 A JPS60109522 A JP S60109522A
- Authority
- JP
- Japan
- Prior art keywords
- bilobalide
- treatment
- days
- bilobalid
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MOLPUWBMSBJXER-YDGSQGCISA-N bilobalide Chemical compound O([C@H]1OC2=O)C(=O)[C@H](O)[C@@]11[C@@](C(C)(C)C)(O)C[C@H]3[C@@]21CC(=O)O3 MOLPUWBMSBJXER-YDGSQGCISA-N 0.000 title claims abstract description 74
- 239000003814 drug Substances 0.000 title abstract description 6
- 239000000203 mixture Substances 0.000 title description 8
- 206010029333 Neurosis Diseases 0.000 title 1
- 208000015238 neurotic disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 208000012902 Nervous system disease Diseases 0.000 claims description 15
- 208000025966 Neurological disease Diseases 0.000 claims description 15
- 201000001119 neuropathy Diseases 0.000 claims description 6
- 230000007823 neuropathy Effects 0.000 claims description 6
- 206010048962 Brain oedema Diseases 0.000 claims description 4
- 208000006752 brain edema Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 208000014644 Brain disease Diseases 0.000 claims description 2
- 102000006386 Myelin Proteins Human genes 0.000 claims 1
- 108010083674 Myelin Proteins Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000005012 myelin Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 244000194101 Ginkgo biloba Species 0.000 description 6
- PIMYDFDXAUVLON-UHFFFAOYSA-M chloro(triethyl)stannane Chemical compound CC[Sn](Cl)(CC)CC PIMYDFDXAUVLON-UHFFFAOYSA-M 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000003651 drinking water Substances 0.000 description 4
- 235000020188 drinking water Nutrition 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 4
- 229960004068 hexachlorophene Drugs 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 3
- 235000008100 Ginkgo biloba Nutrition 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 2
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 208000005374 Poisoning Diseases 0.000 description 2
- 206010036105 Polyneuropathy Diseases 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- YNKFCNRZZPFMEX-XHPDKPNGSA-N desmopressin acetate trihydrate Chemical compound O.O.O.CC(O)=O.C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 YNKFCNRZZPFMEX-XHPDKPNGSA-N 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- -1 lactone compound Chemical class 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 229940028441 minirin Drugs 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000003871 white petrolatum Substances 0.000 description 2
- 210000003032 wing Anatomy 0.000 description 2
- 208000000187 Abnormal Reflex Diseases 0.000 description 1
- 206010000171 Abnormal reflexes Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 208000032096 Encephalitic infection Diseases 0.000 description 1
- 206010014607 Encephalitis toxic Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 239000009429 Ginkgo biloba extract Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 208000007125 Neurotoxicity Syndromes Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 241001123663 Penicillium expansum Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000005587 Refsum Disease Diseases 0.000 description 1
- 206010040026 Sensory disturbance Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008321 arterial blood flow Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940068052 ginkgo biloba extract Drugs 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- 229930184727 ginkgolide Natural products 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000028756 lack of coordination Diseases 0.000 description 1
- 208000036546 leukodystrophy Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 208000019629 polyneuritis Diseases 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 208000022076 postinfectious encephalitis Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3338995.0 | 1983-10-27 | ||
| DE19833338995 DE3338995A1 (de) | 1983-10-27 | 1983-10-27 | Bilobalid enthaltende arzneimittel |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60109522A true JPS60109522A (ja) | 1985-06-15 |
| JPS6241688B2 JPS6241688B2 (en, 2012) | 1987-09-04 |
Family
ID=6212873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59225657A Granted JPS60109522A (ja) | 1983-10-27 | 1984-10-26 | 神経病の治療のためのビロバリド含有製剤組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US4571407A (en, 2012) |
| EP (1) | EP0143977B1 (en, 2012) |
| JP (1) | JPS60109522A (en, 2012) |
| AT (1) | ATE119772T1 (en, 2012) |
| CA (1) | CA1238280A (en, 2012) |
| DE (2) | DE3338995A1 (en, 2012) |
| IE (1) | IE66527B1 (en, 2012) |
| ZA (1) | ZA848369B (en, 2012) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002522387A (ja) * | 1998-08-07 | 2002-07-23 | ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツプリカーション・シヤンテイフイツク・（エス．セー．エール．アー．エス） | 筋萎縮性側索硬化症の治療薬を製造するためのイチョウ抽出物の使用 |
| JP2007099660A (ja) * | 2005-10-03 | 2007-04-19 | Tokiwa Shokubutsu Kagaku Kenkyusho:Kk | 抗うつ剤 |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3645254C2 (de) * | 1986-08-01 | 1994-06-09 | Mattern Geb Eckhardt Claudia | Arzneimittel gegen Schwangerschaftsübelkeit und -erbrechen |
| US5895785A (en) * | 1987-10-20 | 1999-04-20 | Ruth Korth | Treatment and prevention of disorders mediated by LA-paf or endothelial cells |
| EP0540767B9 (en) * | 1991-11-04 | 2004-12-22 | Korth, Ruth-Maria, Dr. med | Treatment and prevention of mental diseases mediated by elevated lyso paf levels with paf antagonists |
| US5530023A (en) * | 1987-10-20 | 1996-06-25 | Korth; Ruth | Production of binding sites for PAF, PAF analogues and PAF antagonists in endothelial cells |
| ES2043897T3 (es) * | 1988-01-28 | 1994-01-01 | Koeltringer Peter | Preparado de combinacion, en especial para el tratamiento de enfermedades de las celulas nerviosas. |
| DE3802895A1 (de) * | 1988-02-01 | 1989-08-10 | Koeltringer Peter | Kombinationspraeparat zur behandlung von nervenzell- und nervenfasererkrankungen und verletzungen |
| ATE81015T1 (de) * | 1988-07-19 | 1992-10-15 | Abraxas Bio Labs Sa | Aus gingko biloba extrahierter biologischer regulator, wirksam in verschiedenen pathologien. |
| US5637302A (en) * | 1988-09-20 | 1997-06-10 | Indena Spa | Extracts of Ginkgo biloba and their methods of preparation |
| JP2818220B2 (ja) * | 1988-11-04 | 1998-10-30 | フロイント産業株式会社 | 食品用の含水有機溶剤抽出物含有組成物および医薬用の含水有機溶剤抽出物含有組成物、並びにそれらの製造方法 |
| DE3840832A1 (de) * | 1988-12-03 | 1990-06-07 | Mueller Robert Dr | Aeusserlich anzuwendendes praeparat |
| DE3940092A1 (de) * | 1989-12-04 | 1991-06-06 | Schwabe Willmar Gmbh & Co | Extrakt aus blaettern von ginkgo biloba, verfahren zu seiner herstellung und den extrakt enthaltende arzneimittel |
| DE3940094A1 (de) * | 1989-12-04 | 1991-06-06 | Montana Ltd | Wirkstoffkonzentrate und neue wirkstoff-kombinationen aus blaettern von ginkgo biloba, ein verfahren zu ihrer herstellung und die wirkstoff-konzentrate bzw. die wirkstoff-kombinationen enthaltenden arzneimittel |
| US5158770A (en) * | 1989-12-29 | 1992-10-27 | Freund Industrial Co., Ltd. | Aqueous solution containing ginkgo leaf extract |
| IT1238684B (it) * | 1990-02-09 | 1993-09-01 | Indena Spa | Derivati del bilobalide,loro usi e formulazioni che li contegono |
| US6001393A (en) * | 1990-08-20 | 1999-12-14 | Daoud; Abdulwahid H. | Ginkgo biloba extract enhanced bioavailability composition and food products |
| JP3188461B2 (ja) * | 1991-12-23 | 2001-07-16 | ドクター・ビィルマール・シュバーベ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・カンパニー | 緊張及び不安の処置のためのビロバリドを含有する医薬製剤 |
| US5455232A (en) * | 1992-02-04 | 1995-10-03 | Piljac; Goran | Pharmaceutical preparation based on rhamnolipid |
| GB9202993D0 (en) * | 1992-02-13 | 1992-03-25 | Indena Spa | Novel pharmaceutical uses of bilobalide and derivatives thereof and pharmaceutical compositions adapted for such use |
| US5891465A (en) * | 1996-05-14 | 1999-04-06 | Biozone Laboratories, Inc. | Delivery of biologically active material in a liposomal formulation for administration into the mouth |
| EP1033994A4 (en) | 1997-11-25 | 2002-04-03 | Pharmanex Inc | METHOD FOR PRODUCING BIOGINKGO |
| WO1999064028A1 (en) * | 1998-06-11 | 1999-12-16 | Societe De Conseils De Recherches Et D'applications Scientifiques Sas | Protecting neurons from ischemia |
| JP2003519192A (ja) * | 1999-12-30 | 2003-06-17 | プロテオテック・インコーポレーテッド | アルツハイマー病におけるアミロイド症および他のアミロイド症の治療のためのカテキンおよび緑茶抽出物 |
| EP1309335B1 (de) * | 2000-08-17 | 2004-03-10 | Medichemie Ag | Verwendung von extrakten aus ginkgo biloba-blättern zur traumprovokation |
| FR2842425B1 (fr) * | 2002-07-16 | 2005-04-08 | Sod Conseils Rech Applic | Utilisation d'extraits de ginkgo biloba pour favoriser la masse musculaire au detriment de la masse graisseuse |
| FR2827518B1 (fr) * | 2001-07-17 | 2005-07-08 | Sod Conseils Rech Applic | Utilisation d'extraits de ginkgo biloba pour preparer un medicament destine a traiter la sarcopenie |
| US20050015263A1 (en) * | 2001-11-29 | 2005-01-20 | Beal M Flint | Use of gingko biloba extracts to promote neuroprotection and reduce weight loss |
| DE10213571A1 (de) * | 2002-03-26 | 2003-10-23 | Lichtwer Pharma Ag | Pflanzenextrakte und deren Anwendung |
| RU2005137567A (ru) * | 2003-05-02 | 2006-04-27 | Джорджтаун Юниверсити (Us) | Экстракт гинкго билоба как средство для лечения терапевтически индуцированной нейротоксичности |
| US20060069157A1 (en) * | 2004-02-19 | 2006-03-30 | U.S. Department Of Veterans Affairs | Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as Huntington's disease, by sodium butyrate chemotherapy |
| KR100623164B1 (ko) * | 2004-07-22 | 2006-09-19 | 재단법인서울대학교산학협력재단 | 뇌신경 보호효과를 갖는 신규한 은행잎 엑스를 정제하는방법 및 이를 함유하는 조성물 |
| US7901675B2 (en) * | 2004-10-13 | 2011-03-08 | U.S. Department Of Veterans Affairs | Method of using coenzyme Q10 to treat Huntington's disease |
| US20060135612A1 (en) * | 2004-12-17 | 2006-06-22 | U.S. Department Of Veterans Affairs | Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent |
| DE202011108417U1 (de) | 2011-11-29 | 2012-03-01 | Ruth-Maria Korth | Örtliche und dietätische Kompositionen ohne Etherlipide, Etherphospholipide, Alkylradikale, die geeignet sind für sensible Personen |
| EP3682870B1 (de) | 2019-01-15 | 2023-08-30 | Dr. Willmar Schwabe GmbH & Co. KG | Verfahren zur herstellung von leicht einzunehmenden tabletten mit trockenextrakt aus ginkgo biloba blättern |
| CN111803487B (zh) * | 2019-04-10 | 2022-12-02 | 成都百裕制药股份有限公司 | 银杏萜内酯在制备预防和/或治疗吉兰-巴雷综合征药物中的用途 |
-
1983
- 1983-10-27 DE DE19833338995 patent/DE3338995A1/de active Granted
-
1984
- 1984-10-19 US US06/662,598 patent/US4571407A/en not_active Expired - Lifetime
- 1984-10-25 AT AT84112902T patent/ATE119772T1/de not_active IP Right Cessation
- 1984-10-25 EP EP84112902A patent/EP0143977B1/de not_active Expired - Lifetime
- 1984-10-25 DE DE3486378T patent/DE3486378D1/de not_active Expired - Fee Related
- 1984-10-26 ZA ZA848369A patent/ZA848369B/xx unknown
- 1984-10-26 JP JP59225657A patent/JPS60109522A/ja active Granted
- 1984-10-26 CA CA000466409A patent/CA1238280A/en not_active Expired
- 1984-10-26 IE IE276584A patent/IE66527B1/en not_active IP Right Cessation
-
1988
- 1988-10-11 US US07/256,233 patent/US4892883A/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002522387A (ja) * | 1998-08-07 | 2002-07-23 | ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツプリカーション・シヤンテイフイツク・（エス．セー．エール．アー．エス） | 筋萎縮性側索硬化症の治療薬を製造するためのイチョウ抽出物の使用 |
| JP2007099660A (ja) * | 2005-10-03 | 2007-04-19 | Tokiwa Shokubutsu Kagaku Kenkyusho:Kk | 抗うつ剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6241688B2 (en, 2012) | 1987-09-04 |
| ATE119772T1 (de) | 1995-04-15 |
| ZA848369B (en) | 1985-06-26 |
| DE3486378D1 (de) | 1995-04-20 |
| US4892883A (en) | 1990-01-09 |
| IE842765L (en) | 1985-04-27 |
| IE66527B1 (en) | 1996-01-24 |
| EP0143977A2 (de) | 1985-06-12 |
| DE3338995A1 (de) | 1985-05-09 |
| EP0143977A3 (en) | 1987-05-13 |
| EP0143977B1 (de) | 1995-03-15 |
| DE3338995C2 (en, 2012) | 1990-03-22 |
| US4571407A (en) | 1986-02-18 |
| CA1238280A (en) | 1988-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS60109522A (ja) | 神経病の治療のためのビロバリド含有製剤組成物 | |
| POPE Jr et al. | Apparent neuroleptic malignant syndrome with clozapine and lithium | |
| JP6676062B2 (ja) | 認知低下を処置するための方法 | |
| CA2709958C (en) | Use of an extract made of leaves of ginkgo biloba | |
| DE19858789A1 (de) | Kombination von Cerivastatin und Fibraten | |
| DE69209414T2 (de) | Hirnaktivitätfördernde Zubereitungen | |
| WO1995017889A1 (fr) | Composition therapeutique utile pour traiter l'hyperparathyroidie d'un patient en dialyse artificielle | |
| CZ177397A3 (en) | Use of frank incense for preparing a medicament for prophylactic and therapeutic treatment of alzheimer's disease | |
| BR112012017080B1 (pt) | composições compreendendo extratos de andrographis paniculata e ginkgo biloba complexados com fosfolipídeos e seu uso | |
| JPH05194209A (ja) | 血管内皮細胞機能改善剤 | |
| KR20240032789A (ko) | 시클로-히스프로를 유효성분으로 포함하는 비만 예방 또는 치료용 약제학적 조성물 | |
| JPS5938203B2 (ja) | 補酵素ｑを主成分とする脳循環障害治療剤 | |
| EP0618797B1 (de) | Bilobalid enthaltende pharmazeutische zubereitungen zur behandlung von spannungs- und angstzuständen | |
| JPH0699310B2 (ja) | アセトアルデヒド解毒剤 | |
| JPH02212421A (ja) | 痴呆治療剤 | |
| JPS6041611A (ja) | 血中脂質低下剤 | |
| RU2725622C1 (ru) | Фармацевтическая композиция для лечения и/или профилактики заболеваний печени | |
| Epstein | Synthetic antimalarial drug therapy in lupus erythematosus and polymorphous light eruptions | |
| RU2684783C1 (ru) | Композиция антиоксидантов, пригодная для перорального применения в терапии воспалительного процесса в легких | |
| JP2024526939A (ja) | 酸化的網膜疾患の進行を抑制する方法 | |
| KR20030019444A (ko) | 안지오텐신 ⅱ 길항물질의 신규한 용도 | |
| Parkes | Clinical pharmacology of amantadine and derivatives | |
| US3995057A (en) | Ophthalmological method | |
| RU2468813C1 (ru) | Средство для профилактики или лечения острых и хронических нарушений мозгового кровообращения, применение и способ лечения | |
| RU2404976C1 (ru) | Средство, снижающее влечение к алкоголизму, фармацевтическая композиция, способ ее получения, лекарственное средство и способ лечения |